Spiriva
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for use in chronic obstructive pulmonary disease (COPD), and is available in a dry-powder inhaler (HandiHaler) and soft mist inhaler (Respimat) device. Spiriva exhibits pharmacological effects in the airways through inhibition of M1 and M3 receptors at the smooth muscle, leading to bronchodilation. It is indicated for the long-term treatment of COPD-associated bronchospasm and for the management of exacerbations. Spiriva was the first LAMA on the market, making it the gold-standard monotherapy in COPD. It is also approved for use in asthma.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Spiriva : Chronic obstructive pulmonary disease (COPD)
21 Spiriva : Asthma
LIST OF FIGURES
14 Figure 1: Spiriva for COPD – SWOT analysis
15 Figure 2: Datamonitor Healthcare’s drug assessment summary of Spiriva for COPD
16 Figure 3: Datamonitor Healthcare’s drug assessment summary of Spiriva for COPD
18 Figure 4: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
26 Figure 5: Spiriva for asthma – SWOT analysis
27 Figure 6: Datamonitor Healthcare’s drug assessment summary of Spiriva in asthma
28 Figure 7: Datamonitor Healthcare’s drug assessment summary of Spiriva in asthma
30 Figure 8: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Spiriva drug profile
7 Table 2: Spiriva HandiHaler Phase III data in COPD
9 Table 3: Spiriva Respimat Phase III data in COPD
11 Table 4: Spiriva Respimat’s long-term Phase III TIOSPIR study against Spiriva HandiHaler
19 Table 5: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
21 Table 6: Spiriva drug profile
23 Table 7: Spiriva pivotal trial data in asthma
31 Table 8: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Stelara 
Sign up to the